Pharmacy on Demand (PoD)TM

ODP’s breakthrough technology platform, the ‘Pharmacy on Demand’ (PoD)TM, is the world’s most advanced, miniaturized, and automated suite of pharmaceutical manufacturing systems.

ODP is developing a range of new technologies to transform manufacturing along the entire pharmaceutical life cycle—everything from starting materials and active pharmaceutical ingredients (APIs) to formulated medicines (pills, tablets or liquids). We are also developing a novel formulation device to make sterile injectables.

ODP not only manufactures drugs—we also design and manufacture components of our platform (hardware and software) to enable our end-to-end capability.

The PoD platform has produced 16 precursors, 21 APIs, five finished drug tablets, and three sterile injectable formulations. PoD is capable of making hundreds of thousands of doses of medications in just 24 hours and can switch from one medicine to another in just a few hours.

PoDTM

PoD is an agile, end-to-end system that can be customized in just hours to make various products—from precursors to final formulated drugs.

PoD incorporates advanced in-process monitoring utilizing propriety state-of-the-art quality management systems that enables real-time, “every” dose monitoring. This technology surpasses the quality standards currently required in traditional batch processing.

PoD Technologies available or in development:

American Made Precursors on Demand (AMPoDTM)
  • AMPoDTM converts U.S.-sourced raw chemical products or feedstocks into key starting materials or precursors for a specific active pharmaceutical ingredient (API).
BioModTM
  • BioModTM is a compact and robust system, designed for the automated manufacture of biologics at the point-of-care.
IV Medicines on DemandTM (formulator)
  • Our formulator is a proprietary technology used in the PoD system to produce sterile injectables. The first injectables being produced are COVID-19 targets selected by the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services.

PoD Solutions and Benefits

Revolutionizing where and how medicines are made.

When a local or regional crisis strikes—pandemic, natural disaster, supply chain shortage or disruption— PoD can provide a responsive, customizable and fast solution.

Medicines can be manufactured when and where they are needed, from the front lines to fire stations, from hospitals to remote villages.

A distributed network of PoDs will reduce vulnerabilities associated with an over-reliance on centralized manufacturing and processing models.

PoD offers greater volume versatility over traditional batch manufacturing. It can make 100s to millions of doses depending on the need.

PoD will improve the reliability and responsiveness of our medicine supply chain.

PoD can stabilize pricing by enabling ‘just in time’ manufacturing capability that reduces the need to stockpile large supplies of medicines and is more responsive to surges in demand.

PoD is uniquely designed to meet the needs of the precision medicine frontier and to address orphan and rare diseases. As medicines become more personalized, the PoD technology can provide a cost-effective manufacturing option.

PoD is a greener pharmaceutical manufacturing solution with the potential to reduce waste by manufacturing what is needed when it is needed and reducing waste throughout the product lifecycle (e.g. storage, distribution, expirations), creating a positive environmental impact.

Establishing A Federal Adaptive, and On-Demand PoD NetworkTM

To improve national security and achieve the goal of medicine self-sufficiency, ODP aims to build a network of PoD systems, distributed across the country, with each capable of creating critical starting materials, APIs, and formulated drugs on demand, when and where they are needed. With the PoD network, we will be able to rapidly and flexibly respond to critical medicine needs in the U.S., which will revolutionize how medicines are sourced, manufactured, and distributed.

This ‘Made in America’ manufacturing capability and strategic asset will mitigate drug shortages during both peacetime and crises, improve our readiness to biomedical threats, create new, high-paying U.S. jobs, reduce U.S. dependence on foreign manufacturers, advance the U.S.’s innovation prowess, and usher in a technology revolution that will leapfrog our legacy 19th century industrial manufacturing processes.